BenzingaAugust 19, 2026 at 2:07 AM NY2 Months Ago
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
